Corporate News: Bond Issues, Personnel Changes, and Infrastructure Development
Companies are announcing new debt obligations, contract updates, and operational expansion.

ABT Health Care · 3 analyses
Abbott Laboratories reported $13B in revenue (+14.5% YoY), compared with a +7.2% median across covered Health Care peers. 1 insider sale recorded.
Companies are announcing new debt obligations, contract updates, and operational expansion.
Abbott Laboratories reported third-quarter 2026 revenue of $13.0 billion, up 14.5% year-over-year. Amid rising operating expenses and the integration of Exact Sciences, acquired in March 2026, Abbott’s net income fell 44% to $920 million.
Abbott announced its intention to separate its nutrition business, with annual sales of about $8.5 billion, into an independent public company. Abbott shareholders will receive shares of the new company, and the deal is planned to close by the end of 2027.
ABBOTT LABORATORIES: 12 recorded developments from 4 official sources in 2026-10.
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
From the 10-Q for the period ended September 30, 2026, filed November 4, 2026. SEC
| Latest | Earlier | Change | |
|---|---|---|---|
| Revenue quarter | $13B | $11.4B | +14.5% |
| Operating income quarter | $1.4B | $2.1B | -34.0% |
| Net income quarter | $920M | $1.6B | -44.0% |
| Diluted EPS quarter | $0.53 | $0.94 | -43.6% |
| Dividends per share quarter | $0.63 | $0.59 | +6.8% |
| Operating cash flow year to date | $5.5B | $6.3B | -11.4% |
| Cash and cash equivalents balance | $4.1B | $8.5B | -52.5% |
| Long-term debt balance | $29.5B | $9.9B | +197.6% |
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Abbott Laboratories ABT | $13B | +14.5% | 10.4% |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|---|---|
| November 16, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|---|---|---|---|---|---|
| November 5, 2026 | Mary K Moreland | Sale notice filed | 3,500 | $116.00 | $406,000 | SEC |
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 151,666,065 | $14,989,157,224 | -0.6% | Q3 2026 |
| State Street | 81,431,110 | $8,047,836,601 | +0.6% | Q3 2026 |
| Capital Research Global Investors | 44,980,846 | $4,445,523,747 | +21.9% | Q3 2026 |
| Geode Capital Management | 39,587,887 | $3,894,300,713 | +0.9% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 23,354,911 | $2,119,224,624 | — | Q2 2026 |
| Fidelity (FMR) | 14,403,368 | $1,423,484,868 | +7.3% | Q3 2026 |
| Two Sigma Investments | 5,005,388 | $494,682,496 | -38.4% | Q3 2026 |
| Wellington Management | 4,651,088 | $459,667,027 | -44.0% | Q3 2026 |
| Millennium Management | 2,096,054 | $207,153,017 | -41.8% | Q3 2026 |
| Citadel Advisors | 1,699,017 | $167,913,850 | -80.2% | Q3 2026 |
| Renaissance Technologies | 458,466 | $45,310,195 | -33.2% | Q3 2026 |
| D. E. Shaw & Co. | 363,307 | $35,905,630 | -75.1% | Q3 2026 |
| Bridgewater Associates | 55,789 | $5,513,627 | -6.7% | Q3 2026 |
| Soros Fund Management | 44,750 | $4,422,643 | 0.0% | Q3 2026 |
| T. Rowe Price | 23,546,479 | $2,327,100 | +3.3% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.